FDA approves Cellestis' latent TB (tuberculosis) test:
This article was originally published in Clinica
The US FDA has approved for sale Cellestis' blood test for latent tuberculosis (TB) infection. The QuantiFERON-TB test is based on the measurement of IFN-gamma secreted from stimulated T cell lymphocytes previously exposed to Mycobacterium tuberculosis infection. The assay involves an overnight culture of whole blood with tuberculin and control antigens, followed by detection of IFN-gamma in a rapid, single-step, sandwich ELISA. The accurate identification of individuals with latent TB infection is crucial to the goal of TB elimination, says the Australian biotechnology firm.
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.